Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy

Currently interferon alfa-2b (IFNα-2b) is an approved adjuvant drug for high-risk melanoma patients that leads to an improvement in disease-free survival (DFS). However, it is unclear whether it also impacts overall survival. Widespread use of adjuvant high-dose IFNα has been tempered by its signifi...

Full description

Bibliographic Details
Main Authors: Kaehler, Katharina C., Blome, Christine, Forschner, Andrea, Gutzmer, Ralf, Haalck, Thomas, Heinzerling, Lucie, Kornek, Thomas, Livingstone, Elisabeth, Loquai, Carmen, Maul, Lara Valeska, Lang, Berenice M., Schadendorf, Dirk, Stade, Barbara, Terheyden, Patrick, Utikal, Jochen, Wagner, Tobias, Hauschild, Axel, Garbe, Claus, Augustin, Matthias
Format: Online
Language:English
Published: Wolters Kluwer Health 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120927/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120927/

Similar Items